circulating tumor DNA molecular residual disease positive
1 drugsPredictive biomarker for patient selection in 6 indications
1
Approved Drugs
6
Indications
1
Companies
circulating tumor DNA molecular residual disease positive is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 6 indications including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing circulating tumor DNA molecular residual disease positive drugs below.
Search circulating tumor DNA molecular residual disease positive Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting circulating tumor DNA molecular residual disease positive
| Drug | Company | Therapeutic Area |
|---|---|---|
| TECENTRIQ HYBREZA | Roche | Oncology |
circulating tumor DNA molecular residual disease positive Indications
Non-Small Cell Lung Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer